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ABSTRACT Poikilodermatous mycosis fungoides (PMF) is a rare clinical vari-
ant of early-stage MF with peculiar histological features. Poikiloderma oc-
curs in many different clinical conditions, which makes a diagnostic proce-
dure more complicated. PMF belongs to a group of MF variants with low 
risk of disease progression. We report a case of a 64-year-old woman, who 
presented with mottled skin aspect of erythema, poikilodermatous patches 
(hypopigmentation, hyperpigmentation, atrophy, and telangiectasia) on 
more than 80% of the body. Based on clinical, histopathological, and im-
munohistochemical findings, we established the diagnosis of PMF. Staging 
procedure determined stage IIA. As skin-directed therapy was the treatment 
of choice, the patient was successfully treated with psoralen-UVA (PUVA), 
nbUVB plus retinoid (Re-nbUVB), and PUVA plus retinoid (Re-PUVA), how-
ever, with rapid recurrence. 
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INTRODUCTION
Mycosis fungoides (MF) is the most common 
type of cutaneous lymphoma. MF shows varieties in 
both its clinicopathological presentation and immu-
nophenotype. Poikilodermatous mycosis fungoides 
(PMF), also called poikiloderma vasculare atrophicans 
(PVA), is a rare clinical variant of early-stage MF, char-
acterized by localized or diffuse large macules and 
patches of mottled hypopigmentation and hyper-
pigmentation with atrophy and prominent telangiec-
tasia (poikiloderma). Lesions have a predilection for 
the trunk (especially breasts) and buttocks, but they 
may be generalized (1,2). Rarely, the retiform pattern 
of atrophic patches occurs, which was previously 
termed parakeratosis variegata (3). Some authors de-
fine PVA as a clinicopathological entity distinct from 
PMF because PVA has CD8+ T-cell infiltrate and a long 
benign course (4). PMF usually presents at a younger 
age than classic MF and is more frequently associated 
with lymphomatoid papulosis (5). The lesions may be 
asymptomatic, rarely mildly pruritic, or with a sting-
ing sensation. Histological findings in PMF are: atro-
phic epidermis, loss of rete ridges, band-like infiltrate 
of lymphocytes, epidermotropism, dilated capillaries, 
necrotic keratinocytes, pigment incontinence, and a 
thickened papillary dermis (2). Histopathological and 
immunological features of PMF are similar to those of 
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classic MF in early stages with CD2+, CD3+, CD4+, CD7, 
CD45RO+, CD8- T-cell immunophenotype, although 
some recent studies and case reports suggest a cyto-
toxic phenotype (CD8+, CD4-, CD56+) (5). Poikiloder-
ma occurs in many clinical conditions that should be 
considered in differential diagnosis: dermatomyositis, 
lupus erythematosus, systemic sclerosis, pigmented 
atrophic lichen planus, poikiloderma of Civatte, xe-
roderma pigmentosum, Kindler syndrome, etc.(4). 
Treatment of PMF depends on disease stage, patient 
age, and general health, and includes both skin-di-
rected and systemic treatments. PMF has a lower risk 
of disease progression and better survival, just like 
hypopigmented MF, when compared with other clini-
cal variants of MF (6).
CASE PRESENTATION
We report a case of a 64-year-old woman who pre-
sented to our Dermatology Department with mottled 
skin aspect of erythema, patches with hypopigmenta-
tion, hyperpigmentation, atrophy, and telangiectasia 
localized on the trunk and upper and lower extremi-
ties involving more than 80% of the body surface (Fig-
ure 1). She complained of itching and reported first 
lesion onset at age 59 on her right breast followed by 
similar lesions on the abdomen, with periods of almost 
complete remission after sun exposure. Her personal 
and family medical history was without significance 
for diagnosis. Two biopsy specimens were taken from 
lesions in the gluteal and presternal region. Histopa-
thology revealed epidermotropism with Pautrier’s 
microabscesses (PMAs), basal alignment of atypical 
lymphocytes, and lichenoid dermal infiltrate of atypi-
cal lymphocytes (Figure 2). Immunohistochemical 
evaluation showed small atypical CD3+, CD4+, CD2+, 
CD5-, CD7- T-lymphocytes in the dermis and epidermis 
and scattered CD8+ lymphocytes within the epidermis 
(Figure 3). The diagnosis of PMF was established ac-
cording to clinical findings, histology, and immuno-
histochemistry. Computed tomography (CT) scans of 
the thorax, abdomen, and pelvis, as well as aspiration 
of the sternal bone marrow for cytological assess-
ment were performed to determine the stage of the 
disease. Laboratory data: C-reactive protein (CRP) 11.1 
(normal range 0.0-5.0mg/L), lactate dehydrogenase 
(LDH) 173 (normal <240 U/L), triglycerides 3.8 (<1.7 
mmol/L). Only reactive lymphadenopathy was found 
(axillary lymph nodes and inguinal up to 1.3 cm × 1cm, 
histologically uninvolved). As investigations excluded 
extracutaneous disease involvement, PMF stage IIA 
(T2N1M0) was determined. We decided to start PUVA 
therapy: UVA irradiation two hours after oral admin-
istration of 8-methoxypsoralen (8-MOP) 40 mg/daily. 
The patient received a cumulative UVA dose of 21.5 
J/cm2 during a course of 13 exposures that resulted 
in only partial regression of erythema and induration. 
Figure 1. Clinical findings: mottled skin aspect of erythema, patches with hypopigmentation, hyperpigmentation, atrophy, 
and telangiectasia (poikiloderma) involving more than 80% of the body surface.
Figure 2. Histological features: atrophic and flattened epidermis, dilated blood vessels, epidermotropism, basal alignment of 
atypical lymphocytes, and lichenoid dermal infiltrate of atypical lymphocytes (hematoxylin and eosin, ×10).
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Subsequently, we decided to add oral retinoid (acitre-
tin 30 mg/daily) and perform Re-PUVA with the addi-
tional local application of betamethasone cream twice 
daily for two weeks. The patient received an additional 
cumulative UVA dose of 7.5 J/cm2 during a course of 
another nine exposures that resulted in complete re-
gression of erythema and loss of induration.
The patient was readmitted to the hospital due 
to recurrence of skin lesions after five months. This 
time she was treated with PUVA therapy and received 
a cumulative UVA dose of 8.5 J/cm2 during a course 
of eight exposures, but the therapy was discontinued 
due to unavailability of 8-MOP on the market. There-
fore, combined treatment with acitretin (initial dose 
of 50 mg/daily) and nbUVB phototherapy (Re-nbUVB) 
was started. Betamethasone cream was applied twice 
daily for two weeks. The patient received a cumula-
tive nbUVB dose of 5.8 J/cm2 during a course of elev-
en exposures that resulted in complete regression of 
erythema and partial loss of induration.
Due to worsening of the disease in the form of 
erythema, poikilodermatous patches, and plaques, 
pityriasiform desquamation on the upper eyelid 
and scalp, and clinically enlarged submandibular 
lymph nodes, the patient was admitted for the third 
time to the hospital after eleven months. Laboratory 
data showed CRP 13.1 (normal range 0.0-5.0 mg/L), 
LDH 208 (normal <240 U/L), leukocytes 10.9 (3.4-9.7 
10e9/L), triglycerides 2.92 (<1.7 mmol/L). The whole 
staging procedure was performed again. CT scans re-
vealed reactive inguinal and axillary lymphadenopa-
thy (right axillary lymph nodes up to 1.9 cm × 1.3 cm, 
left axillary lymph nodes 1.8 cm × 1.1cm, left inguinal 
lymph nodes up to 1.8 cm × 1.4 cm, histologically un-
involved). PMF stage IIA (T2N1M0) was determined. 
The patient was referred to a hematologist for con-
sultation. Due to a lack of signs of extracutaneous dis-
ease propagation, the hematologist recommended 
PUVA therapy. The patient underwent PUVA therapy 
over the course of twenty exposures (cumulative UVA 
dose 33.5 J/cm2 ) and local betamethasone therapy 
that resulted in complete disappearance of erythema, 
scaling, and induration, leaving only poikiloderma. 
The patient was recommended regular check-ups.
DISCUSSION
Rare clinical variants of MF include hypopigment-
ed MF, granulomatous slack skin, pagetoid reticulosis, 
and folliculotropic and poikilodermatous MF. It is still 
debatable whether PMF is a clinical variant of early-
stage MF or special entity. We must also bear in mind 
the fact that is has been reported that poikiloderma 
can coexist with classical MF lesions, so PMF can only 
be considered when poikilodermatous lesions are 
predominant (>50% of lesions), as in our case where 
poikilodermatous lesions covered almost 80% of the 
body surface (5). 
Histology and immunohistochemistry revealed 
MF, but due to specific clinical findings (poikiloder-
ma), we established the diagnosis of very rare clini-
cal variant – PMF. The most commonly found immu-
nophenotype in PMF is predominantly CD4+ (5), as in 
our case, although the predominance of CD8+ and 
double negative (CD4- and CD8-) was found infre-
quently. Recent data suggest that the CD4+CD8- im-
munophenotype and CD8+CD4- immunophenotype 
in PMF do not differ in prognosis (5). 
T-cell receptor (TCR) gene rearrangement by using 
PCR is not lymphoma-specific; in other words, mono-
clonality does not necessarily mean malignancy (7), 
and positive TCR gene rearrangement (monoclonal-
ity of T-cell infiltrate) is not required for the diagnosis 
(5). Furthermore, monoclonality may be lacking in 
lymphomas and may be found in a distinct propor-
tion of pseudolymphomas (3). Some authors propose 
that undetectable monoclonality should be con-
sidered pre-mycosis (8). A TCR gene rearrangement 
study was not performed in our case.
Lymphadenopathy is a frequent finding in pa-
tients with MF, but it does not necessarily correlate 
with histological lymphomatous involvement. Der-
matopathic lymphadenitis is often observed in such 
patients, as in our case, where the axillary and ingui-
nal lymph nodes were slightly enlarged but still only 
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Figure 3. Immunohistochemical features: tumor cells show epidermotropism with diffuse expression of a) CD3, b) CD4  
(immunohistochemistry CD3 and CD4, ×40).
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up to 2 cm in diameter without histological involve-
ment (9).
Choice of treatment for PMF, as for classic MF, is 
based on staging and includes skin-directed thera-
pies (topical corticosteroids, bexarotene, carmustine, 
mechlorethamine, nbUVB, PUVA, radiation) and sys-
temic therapies. PUVA and nbUVB were found to be 
equally effective (with complete response to treat-
ment in approximately 60% of patients) in retrospec-
tive studies with early-stage MF (10,11). Narrowband 
UVB therapy should be included in first-line treat-
ment options of MF given its efficacy, convenience, 
and the likelihood of fewer long-term adverse effects 
only for the patch stage (11). New treatment options 
for MF have recently expanded to include UVA1 and 
excimer laser (12). A combination of PUVA with sys-
temic therapy is used to diminish the total UVA ex-
posure and therefore minimize the long-term side-ef-
fects. The most common systemic drugs for use with 
PUVA in MF are either retinoids (acitretin, isotretinoin, 
and bexarotene) or interferon-alfa. However, it is still 
an open question whether combination treatments 
are more efficacious than PUVA alone in early disease 
(12). PUVA is more effective than UVB for thicker le-
sions – plaques – or in individuals with dark skin be-
cause UVA penetrates deeper than UVB (12). PUVA 
therapy is associated with an increased risk of non-
melanoma skin cancer, and maintenance therapy is 
not recommended because prolonged disease-free 
intervals are possible. Combined PUVA and retinoid 
therapy may be considered in patients who rapidly 
relapse after PUVA treatment, as was the case with 
our patient. Also, hyper- and hypopigmentation will 
not resolve after treatment, in contrast to erythema, 
itching, desquamation, and induration that are treat-
able (5). PUVA, Re-PUVA, and Re-nbUVB therapy in 
our patient resulted in residual hyper- and hypopig-
mentations. A case of treatment failure of PMF pre-
senting with erythroderma has also been reported in 
the literature (13). 
The overall prognosis for PMF is favorable (most 
patients will have non-progressive disease), although 
recent study revealed PMF cases with progression 
to lymphomatoid papulosis stage III (LyP) and PMF 
stage IVB (5). 
CONCLUSION
PMF is a rare clinical entity with little data in the 
literature on its clinical, histopathological, immuno-
phenotypic, molecular, and prognostic features. We 
can conclude from published data that first-line treat-
ment for PMF (stages IA, IB, IIA) in the patch-stage 
could be nbUVB and for plaque-stage PUVA. In our 
case, Re-PUVA had very good treatment results, and 
this combined therapy probably resulted in fewer 
treatment sessions and lower cumulative UVA dose. 
An individual approach is obligatory as different 
treatment modalities could be successful in the case 
of early-stage PMF. PMF must be considered a ma-
lignant disease that may stay at the same stage with 
many rapid/non-rapid recurrences or may progress. 
Although overall prognosis is good, careful monitor-
ing and appropriate treatment of PMF is necessary.  
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